Phase 3 Readout
MESO: Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Ad
July 1, 2028 · remestemcel-l-rknd. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 1, 2028
- Company
- Mesoblast Limited (MESO)
- Drug
- remestemcel-l-rknd
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Ad
- Company
- Mesoblast Limited (MESO)
- Drug
- remestemcel-l-rknd
- Indication
- GVHD - Graft-Versus-Host Disease